These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 12121832)

  • 1. The development and clinical use of trastuzumab (Herceptin).
    Harries M; Smith I
    Endocr Relat Cancer; 2002 Jun; 9(2):75-85. PubMed ID: 12121832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials.
    Viani GA; Afonso SL; Stefano EJ; De Fendi LI; Soares FV
    BMC Cancer; 2007 Aug; 7():153. PubMed ID: 17686164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Demands for 'off-licence' access to trastuzumab (Herceptin): content analysis of UK newspaper articles.
    Hind D; Wailoo AJ; Sutcliffe P
    Health Expect; 2011 Mar; 14(1):38-47. PubMed ID: 20673243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
    Slamon DJ; Clark GM; Wong SG; Levin WJ; Ullrich A; McGuire WL
    Science; 1987 Jan; 235(4785):177-82. PubMed ID: 3798106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Herceptin.
    Shepard HM; Jin P; Slamon DJ; Pirot Z; Maneval DC
    Handb Exp Pharmacol; 2008; (181):183-219. PubMed ID: 18071947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humanization of an anti-p185HER2 antibody for human cancer therapy.
    Carter P; Presta L; Gorman CM; Ridgway JB; Henner D; Wong WL; Rowland AM; Kotts C; Carver ME; Shepard HM
    Proc Natl Acad Sci U S A; 1992 May; 89(10):4285-9. PubMed ID: 1350088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor.
    Hudziak RM; Lewis GD; Winget M; Fendly BM; Shepard HM; Ullrich A
    Mol Cell Biol; 1989 Mar; 9(3):1165-72. PubMed ID: 2566907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab: A review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.
    Garnock-Jones KP; Keating GM; Scott LJ
    Drugs; 2010; 70(2):215-39. PubMed ID: 20108993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.
    Baselga J; Norton L; Albanell J; Kim YM; Mendelsohn J
    Cancer Res; 1998 Jul; 58(13):2825-31. PubMed ID: 9661897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab--mechanism of action and use in clinical practice.
    Hudis CA
    N Engl J Med; 2007 Jul; 357(1):39-51. PubMed ID: 17611206
    [No Abstract]   [Full Text] [Related]  

  • 11. Trastuzumab in the Treatment of Breast Cancer.
    Maximiano S; Magalhães P; Guerreiro MP; Morgado M
    BioDrugs; 2016 Apr; 30(2):75-86. PubMed ID: 26892619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product.
    Fendly BM; Winget M; Hudziak RM; Lipari MT; Napier MA; Ullrich A
    Cancer Res; 1990 Mar; 50(5):1550-8. PubMed ID: 1689212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer.
    Albanell J; Baselga J
    Drugs Today (Barc); 1999 Dec; 35(12):931-46. PubMed ID: 12973420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacology of trastuzumab.
    Levêque D; Gigou L; Bergerat JP
    Curr Clin Pharmacol; 2008 Jan; 3(1):51-5. PubMed ID: 18690878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab.
    Cho HS; Mason K; Ramyar KX; Stanley AM; Gabelli SB; Denney DW; Leahy DJ
    Nature; 2003 Feb; 421(6924):756-60. PubMed ID: 12610629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines.
    Collins DM; O'Donovan N; McGowan PM; O'Sullivan F; Duffy MJ; Crown J
    Ann Oncol; 2012 Jul; 23(7):1788-95. PubMed ID: 22056974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth.
    Sarup JC; Johnson RM; King KL; Fendly BM; Lipari MT; Napier MA; Ullrich A; Shepard HM
    Growth Regul; 1991 Jun; 1(2):72-82. PubMed ID: 1688187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Herceptin: mechanisms of action and resistance.
    Nahta R; Esteva FJ
    Cancer Lett; 2006 Feb; 232(2):123-38. PubMed ID: 16458110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
    Baselga J; Tripathy D; Mendelsohn J; Baughman S; Benz CC; Dantis L; Sklarin NT; Seidman AD; Hudis CA; Moore J; Rosen PP; Twaddell T; Henderson IC; Norton L
    J Clin Oncol; 1996 Mar; 14(3):737-44. PubMed ID: 8622019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic.
    Shepard HM; Lewis GD; Sarup JC; Fendly BM; Maneval D; Mordenti J; Figari I; Kotts CE; Palladino MA; Ullrich A
    J Clin Immunol; 1991 May; 11(3):117-27. PubMed ID: 1679763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.